- Ceapro Inc. (TSXV:CZO) has entered into a research collaboration with the Angiogenesis Foundation
- The purpose of the research partnership is to focus on addressing the root cause of disease and tissue damage for diseases like COVID-19
- Under the collaboration, pre-clinical studies using methods by the Angiogenesis Foundation will be used to characterize the in vitro bioactivity of the company’s oat-derived products, among others
- Shares of Ceapro are up 7.94 per cent to C$0.68 as of 2:56 p.m. EDT
Ceapro Inc. (CZO) has entered into a research collaboration with the Angiogenesis Foundation.
According to the release, the collaboration has been developed out of preliminary in vitro results that show Ceapro’s pharmaceutical grade formulations of beta-glucan and avenanthramides stimulate the proliferation and migration of vascular endothelial cells
The research collaboration will focus on addressing the root causes of diseases and tissue damages resulting from conditions such as COVID-19.
Dr. Vincent W. Li, chief scientific officer of the Angiogenesis Foundation, said that endothelial cell stimulation is required for wound healing.
Thanks to Ceapro’s products having demonstrated in vitro activity that could impact wound healing at the cellular level, Li said that the collaboration will characterize this activity using in vitro models and assess their potential applications for various health benefits.
“These benefits include tissue regeneration and repair as well as disease conditions such as COVID-19 and post-COVID-19, which are associated with severe blood vessel damage leading to thrombosis in the lungs and other organs. We believe this has the potential to address a root cause of such complications,” he said.
Gilles R. Gagnon, president and CEO of Ceapro, added that the collaboration will help his company evolve into a life sciences company focused on inflammation and immune-based and lifestyle diseases while expanding the potential of the company’s technology and bioactive products.
Based in Canada, Ceapro is focused on developing proprietary extraction technology and applying the technology to producing extracts as active ingredients from oats and other plant resources.
Shares of Ceapro are up 7.94 per cent to C$0.68 as of 2:56 p.m. EDT.